Open AccessTherapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
Author(s) -
Kucukyurt Selin,
Yagiz Ozogul Yeliz,
Ercaliskan Abdulkadir,
Kabasakal Levent,
Eskazan Ahmet Emre
Publication year - 2020
Publication title -
cancer reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 5
ISSN - 2573-8348
DOI - 10.1002/cnr2.1282
Subject(s) - radionuclide therapy , medicine , myeloid leukemia , neuroendocrine tumors , peptide receptor , oncology , tyrosine kinase inhibitor , somatostatin receptor , leukemia , targeted therapy , imatinib mesylate , imatinib , somatostatin , cancer , receptor
Background Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity. Methods We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy. Results Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases. Conclusions The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.